Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IX001 TCR-T in Advanced Pancreatic Cancer With KRAS G12V Mutation
NCT06898385Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IX001 TCR-T cells in pancreatic cancer (PC), sponsored by Sun Yat-sen University. Primary endpoints: Dose-limiting Toxicity at 4 weeks, Adverse Events at 2 years and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
IX001 TCR-T cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06898385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898385.